Drug Name:
EXELON Rx
Generic Name and Formulations:
Rivastigmine (as tartrate) 1.5mg, 3mg, 4.5mg, 6mg; caps.
Company:
Novartis Pharmaceuticals Corp
Therapeutic Use:
Indications for EXELON:
Mild-to-moderate dementia of the Alzheimer's type.
Adult:
Take with food in the AM and PM. Initially 1.5mg twice daily; if well-tolerated, may increase by 1.5mg twice daily at intervals of at least 2 weeks. Usual range: 6–12mg/day; max 12mg/day. If dose is not tolerated, suspend for several doses and restart at same or next lower dose. If stopped for >3 days, restart at 1.5mg twice daily and retitrate. Moderate-to-severe renal or mild-to-moderate hepatic impairment: use lower doses. Low body wt. (<50kg): monitor for toxicities and consider reducing dose.
Children:
<18yrs: not recommended.
Contraindications:
Patches: previous history of application site reactions suggestive of allergic contact dermatitis (in the absence of negative allergy testing).
Warnings/Precautions:
Monitor for nausea, vomiting, anorexia, weight loss, GI bleed. Sick sinus syndrome, other supraventricular conduction disturbances. Seizures. History or risk of ulcers. Urinary obstruction. Asthma. COPD. Discontinue if disseminated allergic dermatitis occurs. Renal or hepatic impairment. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Reversible acetylcholinesterase inhibitor (carbamate deriv).
Interactions:
Concomitant metoclopramide, beta-blockers, cholinomimetics, anticholinergics: not recommended. May potentiate succinylcholine-type muscle relaxants. Monitor for GI bleed with NSAIDs.
Adverse Reactions:
Nausea, vomiting, anorexia, dyspepsia, asthenia, diarrhea, abdominal pain, dizziness, weight loss, tremor, cholinergic effects; also, patches: application site reactions, allergic contact dermatitis (discontinue if suspected or no improvements within 48hrs after removal; or consider switching to oral form only after negative allergy testing; monitor).
Generic Availability:
YES
How Supplied:
Caps—60, 500; Patches—30
Indications for EXELON:
Mild-to-moderate dementia associated with Parkinson's disease.
Adult:
Take with food in the AM and PM. Initially 1.5mg twice daily; if tolerated, may increase by 1.5mg twice daily at intervals of at least 4 weeks. Usual range: 3–12mg/day; max 12mg/day. If dose is not tolerated, suspend for several doses and restart at same or next lower dose. If stopped for >3 days restart at 1.5mg twice daily and retitrate. Moderate-to-severe renal or mild-to-moderate hepatic impairment: use lower doses. Low body wt. (<50kg): monitor for toxicities and consider reducing dose. Patch: Apply to clean, dry, hairless intact skin. Rotate application site (allow 14 days before reapplying to same site). Initially apply one 4.6mg/24hrs patch once daily; if tolerated, may increase to 9.5mg/24hrs patch after 4 weeks at previous dose; can further be increased to max 13.3mg/24hrs dose. If dosing interrupted for >3 days, restart with 4.6mg/24hrs patch and retitrate. Mild-to-moderate hepatic impairment: initial and max dose 4.6mg/24hrs patch. Low body wt. (<50kg): monitor for toxicities and consider reducing maintenance dose to 4.6mg/24hrs patch. Switching from capsules: see full labeling.
Children:
<18yrs: not recommended.
Contraindications:
Patches: previous history of application site reactions suggestive of allergic contact dermatitis (in the absence of negative allergy testing).
Warnings/Precautions:
Monitor for nausea, vomiting, anorexia, weight loss, GI bleed. Sick sinus syndrome, other supraventricular conduction disturbances. Seizures. History or risk of ulcers. Urinary obstruction. Asthma. COPD. Discontinue if disseminated allergic dermatitis occurs. Renal or hepatic impairment. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Reversible acetylcholinesterase inhibitor (carbamate deriv).
Interactions:
Concomitant metoclopramide, beta-blockers, cholinomimetics, anticholinergics: not recommended. May potentiate succinylcholine-type muscle relaxants. Monitor for GI bleed with NSAIDs.
Adverse Reactions:
Nausea, vomiting, anorexia, dyspepsia, asthenia, diarrhea, abdominal pain, dizziness, weight loss, tremor, cholinergic effects; also, patches: application site reactions, allergic contact dermatitis (discontinue if suspected or no improvements within 48hrs after removal; or consider switching to oral form only after negative allergy testing; monitor).
Generic Availability:
YES
How Supplied:
Caps—60, 500; Patches—30
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |